

Patient ID SA00162650	Patient Name TESTINGRNV, RAVMP	Birth Date 1985-04-15	Sex M	Age 38
Order Number SA00162650	Client Order Number SA00162650	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Oct 2023 07:00		

Ravulizumab Monitoring Panel, S

Ravulizumab Interpretation, S

Ravulizumab Interpretation

1 SDL

No dysfunction in the alternative pathway functional test is detected, consistent with absence of ravulizumab.

Ravulizumab, S

1 SDL


<5.0 mcg/mL

Low

REFERENCE VALUE

Lower limit of quantitation = 5.0 mcg/mL

>175 mcg/mL therapeutic concentration for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

Ravulizumab Complement Blockage, S

1 SDL

109 %of norm
Reference Value
≥46

ADDITIONAL INFORMATION

Monitoring ravulizumab complement blockage is performed by measurement of the alternative complement pathway through AH50 testing.

Received: 05 Oct 2023 08:09

Reported: 06 Oct 2023 07:52

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592